Ivarmacitinib API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ivarmacitinib API 1445987-21-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ivarmacitinib. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ivarmacitinib
- Synonyms:
- Cas Number:
- 1445987-21-2
- DrugBank number:
- DB16756
- Unique Ingredient Identifier:
- K6K4B9Z5TV
General Description:
Ivarmacitinib, identified by CAS number 1445987-21-2, is a notable compound with significant therapeutic applications. Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, graft-versus-host disease, vitiligo, ulcerative colitis, alopecia areata, and primary membranous nephropathy.
Absorption:
The absorption characteristics of Ivarmacitinib are crucial for its therapeutic efficacy: Following oral administration, the median Tmax of ivarmacitinib is approximately one hour. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Ivarmacitinib is an important consideration for its dosing schedule: The half-life of ivarmacitinib following oral administration is 8.33 - 9.87 hours and increases slightly with increasing dosage. This determines the duration of action and helps in formulating effective dosing regimens.
Mechanism of Action:
Ivarmacitinib functions by: Autoimmune inflammatory diseases are thought to arise from a complex interplay of genetics, microbiota, and environmental factors that ultimately lead to dysregulated T- and B-cell activity against the host. Therapeutic interventions are therefore aimed at suppressing T-cell activity and/or blocking cytokine activity. A therapeutic target of particular interest is the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, the dysregulation of which has been implicated in a variety of immune disorders. Put simply, the JAK-STAT pathway plays a significant role in the transduction of signals from cell membrane receptors to the nucleus, and is essential for the transcription of a range of cytokines and growth factors, including those responsible for orchestrating innate and adaptive immune responses. The JAK family of non-receptor tyrosine kinases includes JAK1, JAK2, JAK3, and TYK2, each of which comprise several distinct domains and serve distinct functions. Ivarmacitinib is a highly selective inhibitor of JAK1 - which modulates IL-4, IL-5, IL-13, and IFN-γ, amongst other cytokines - while sparing inhibition of JAK2 in order to decrease the risk of adverse effects like anemia and neutropenia. By inhibiting this pathway, ivarmacitinib may help to prevent the immune dysregulation responsible for a number of inflammatory conditions, including atopic dermatitis and rheumatologic diseases (e.g. rheumatoid arthritis). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Ivarmacitinib is categorized under the following therapeutic classes: Janus Kinase 1, antagonists & inhibitors, Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ivarmacitinib is a type of Dental and Oral Agents
Dental and oral agents belong to the pharmaceutical API category, playing a crucial role in oral health care. These agents are specifically designed to address various dental and oral conditions, ranging from tooth decay and gum diseases to oral infections and inflammation.
One of the primary types of dental and oral agents is antimicrobial APIs. These active pharmaceutical ingredients are known for their ability to inhibit the growth of bacteria and fungi in the oral cavity, helping to prevent and treat infections. Common antimicrobial APIs used in dental and oral care include chlorhexidine, cetylpyridinium chloride, and triclosan.
Another important category is analgesic APIs, which provide pain relief in dental and oral procedures. These agents work by blocking pain signals and reducing inflammation. Popular analgesic APIs in dental care include lidocaine, benzocaine, and ibuprofen.
Fluoride APIs are widely used in dental products to strengthen tooth enamel and prevent tooth decay. These APIs aid in remineralization, making teeth more resistant to acid attacks from bacteria and sugary foods.
Furthermore, there are APIs specifically formulated for treating specific oral conditions such as dry mouth or halitosis. These agents help restore moisture in the mouth and neutralize odor-causing compounds.
Dental and oral agents are typically formulated into various dosage forms, including mouthwashes, toothpaste, gels, and oral sprays. These formulations ensure convenient and effective delivery of the APIs to the affected areas in the oral cavity.
In summary, dental and oral agents are a vital component of oral health care, offering antimicrobial, analgesic, remineralizing, and specific therapeutic benefits. Incorporating these pharmaceutical APIs into dental products helps individuals maintain optimal oral health and prevent dental problems.
